Details

Last Funding Type

Grant

Last Funding Money Raised

$255.98K

Industries

Biopharma,Biotechnology,Life Science,Pharmaceutical

Founded date

Jan 1, 2009

Number Of Employee

1 - 10

Operating Status

Active

Stock Symbol

nasdaq:GRI

Legal Name

GRI Bio Inc.

Also Known As

Glycoregimmune, Inc.,Glycoregimmune,GRI

GRI is a development stage biotech company fundamentally changing the way inflammatory disease is treated. GRI’s Natural Killer T (NKT) cell-based therapies are being developed for liver disease and acute liver failure. NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.

GRI Bio has acquired 1 organizations. Their most recent acquisition was GRI Bio (Reverse Merger With Vallon Pharmaceuticals) on Dec 13, 2022. They acquired GRI Bio (Reverse Merger With Vallon Pharmaceuticals) for 0.

Date Company Name	Industry	Acquisition Type	Price
Dec 13, 2022 GRI Bio (Reverse Merger With Vallon Pharmaceuticals)	Biopharma	merge	—	Detail